Exploratory Studies of Effective Inhibitors against the SARS-CoV-2 Main Protease by Halogen Incorporation and Amide Bond Replacement
-
Published:2023-12-01
Issue:12
Volume:71
Page:879-886
-
ISSN:0009-2363
-
Container-title:Chemical and Pharmaceutical Bulletin
-
language:en
-
Short-container-title:CHEMICAL & PHARMACEUTICAL BULLETIN
Author:
Tsuji Kohei1, Kobayakawa Takuya1, Ishii Takahiro1, Higashi-Kuwata Nobuyo2, Azuma Chika1, Shinohara Kouki1, Miura Yutaro1, Yamamoto Kenichi1, Nishimura Soshi1, Hattori Shin-ichiro2, Bulut Haydar3, Mitsuya Hiroaki2, Tamamura Hirokazu1
Affiliation:
1. Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2. Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute 3. Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health
Publisher
Pharmaceutical Society of Japan
Subject
Drug Discovery,General Chemistry,General Medicine
Reference53 articles.
1. 1) World Health Organization, “WHO Coronavirus (COVID-19) Dashboard.”: ‹https://covid19.who.int/›, cited 28 July, 2023. 2. 2) Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G. F., Tan W., N. Engl. J. Med., 382, 727–733 (2020). 3. 3) Mitsuya H., Kokudo N., Glob. Health Med., 2, 53–55 (2020). 4. 4) Pardo J., Shukla A. M., Chamarthi G., Gupte A., Drugs Context, 9, 2020 (2020). 5. 5) U.S. Food & Drug Administration. “FDA approves first treatment for COVID-19.”: ‹https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19›, cited 28 July, 2023.
|
|